Kevin Kalinsky, MD, MS, discussed selective estrogen receptor downregulators being explored for the treatment of breast cancer clinical trials.
Kevin Kalinsky, MD, MS, associate professor, Department of Hematology and Medical Oncology at Emory University School of Medicine, and the Louisa and Rand Glenn Family chair in Breast Cancer Research, director of the Glenn Family Breast Center, and director of the Breast Medical Oncology at Winship Cancer Institute, discussed selective estrogen receptor downregulators (SERDs) being explored for the treatment of breast cancer.
0:07 | Right now in clinical practice, the only approved selective estrogen receptor down regulator or SERD is fulvestrant [Faslodex]. At San Antonio, we saw the results of the first randomized study with an oral SERD. This was the EMERALD study or assessment versus physician choice, hormonal therapy. And we saw there was a statistically significant improvement in outcomes such as progression-free survival, particularly for those who have ESR1 mutations, which we're seeing [in] about a third of patients with hormone receptor-positive or negative disease, which those tumors have progressed on endocrine therapy.
0:44 | But there are a smattering of other SERDs that are coming down the pike. [These are] randomized studies, including studies with amcenestrant.
1:03 | So, this field is rapidly moving forward, not just anticipated in the metastatic setting, but also in the early-stage setting. And there are some studies that are ongoing and should be opening for patients in the early setting with oral SERDs as well as other hormonal therapies.
Sequencing Sacituzumab and Other Drugs in HR+, HER2- Breast Cancer
May 16th 2024During a Case-Based Roundtable® event, Stephanie L. Graff, MD, discussed multiple later-line treatment options in hormone receptor–positive breast cancer with participants in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Darolutamide Becomes Routine Doublet and Triplet Option in Hormone-Sensitive Prostate Cancer
May 6th 2024Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Read More